Literature DB >> 23820376

E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation.

Savita Lochab1, Pooja Pal1, Isha Kapoor1, Jitendra Kumar Kanaujiya1, Sabyasachi Sanyal1, Gerhard Behre2, Arun Kumar Trivedi3.   

Abstract

Tight control between activation and attenuation of granulocyte colony stimulating factor receptor (G-CSFR) signaling is essential to regulate survival, proliferation and differentiation of myeloid progenitor cells. Previous studies demonstrated negative regulation of G-CSFR through endosomal-lysosomal routing and ubiquitin-proteasome mediated degradation. However, very few E3 ubiquitin ligases are known to target G-CSFR for ubiquitin-proteasome pathway. Here we identified F-box and WD repeat domain-containing 7 (Fbw7), a substrate recognizing component of Skp-Cullin-F box (SCF) E3 ubiquitin Ligase physically associates with G-CSFR and promotes its ubiquitin-mediated proteasomal degradation. Our data shows that Fbw7 also interacts with and degrades G-CSFR-T718 (a truncated mutant of G-CSFR found in severe congenital neutropenia/acute myeloid leukemia (SCN/AML patients)) though at a quite slower rate compared to G-CSFR. We further show that glycogen synthase kinase 3 beta (GSK3β), like Fbw7 also targets G-CSFR and G-CSFR-T718 for degradation; however, Fbw7 and GSK3β are interdependent in targeting G-CSFR/G-CSFR-T718 for degradation because they are unable to degrade G-CSFR individually when either of them is knocked down. We further show that Fbw7 mediated downregulation of G-CSFR inhibits signal transducer and activator of transcription 3 (STAT3) phosphorylation which is required for G-CSF dependent granulocytic differentiation. In addition, our data also shows that inhibition of Fbw7 restores G-CSFR signaling leading to enhanced STAT3 activity resulting in massive granulocytic differentiation. These data indicate that Fbw7 together with GSK3β negatively regulates G-CSFR expression and its downstream signaling.
© 2013.

Entities:  

Keywords:  Fbw7; G-CSFR; GSK3β; Ubiquitin–proteasome degradation

Mesh:

Substances:

Year:  2013        PMID: 23820376     DOI: 10.1016/j.bbamcr.2013.06.018

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Recent advances in SCF ubiquitin ligase complex: Clinical implications.

Authors:  Nana Zheng; Quansheng Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2016-05-05

Review 2.  Targeting the ubiquitin pathway for cancer treatment.

Authors:  Jia Liu; Shavali Shaik; Xiangpeng Dai; Qiong Wu; Xiuxia Zhou; Zhiwei Wang; Wenyi Wei
Journal:  Biochim Biophys Acta       Date:  2014-12-04

3.  E3 Ubiquitin Ligase Fbw7 Negatively Regulates Osteoblast Differentiation by Targeting Runx2 for Degradation.

Authors:  Yogesh Kumar; Isha Kapoor; Kainat Khan; Gatha Thacker; Mohd Parvez Khan; Nidhi Shukla; Jitendra Kumar Kanaujiya; Sabyasachi Sanyal; Naibedya Chattopadhyay; Arun Kumar Trivedi
Journal:  J Biol Chem       Date:  2015-11-05       Impact factor: 5.157

4.  CEACAM-1 Induced CSF3-receptor Downregulation in Bone Marrow Associated With Refractory Neutropenia in Advanced Cirrhosis.

Authors:  Chhagan Bihari; Sukriti Baweja; Seggere Murlaikrishna Shasthry; Deepika Lal; Preeti Negi; Swati Thangariyal; Dinesh Mani Tripathi; Shiv Kumar Sarin
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

Review 5.  Aberrant regulation of FBW7 in cancer.

Authors:  Lixia Wang; Xiantao Ye; Yueyong Liu; Wenyi Wei; Zhiwei Wang
Journal:  Oncotarget       Date:  2014-04-30

6.  Proteomic discovery of MNT as a novel interacting partner of E3 ubiquitin ligase E6AP and a key mediator of myeloid differentiation.

Authors:  Isha Kapoor; Jitendra Kanaujiya; Yogesh Kumar; Jagadeshwar Reddy Thota; Madan L B Bhatt; Naibedya Chattopadhyay; Sabyasachi Sanyal; Arun Kumar Trivedi
Journal:  Oncotarget       Date:  2016-02-16

Review 7.  Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis.

Authors:  Jun Cao; Ming-Hua Ge; Zhi-Qiang Ling
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

Review 8.  FBW7 in hematological tumors.

Authors:  Qiaojuan Zhu; Linjun Hu; Yang Guo; Zunqiang Xiao; Qiuran Xu; Xiangmin Tong
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.